Last reviewed · How we verify
IDP-121
At a glance
| Generic name | IDP-121 |
|---|---|
| Sponsor | IDP Discovery Pharma S.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (PHASE1, PHASE2)
- Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris (PHASE3)
- Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris (PHASE3)
- Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris (PHASE1)
- A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris (PHASE3)
- A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-121 CI brief — competitive landscape report
- IDP-121 updates RSS · CI watch RSS
- IDP Discovery Pharma S.L. portfolio CI